

## Sandostatin® LAR Depot (octreotide) – First-time generic

- On October 1, 2024, <u>Teva launched</u> an <u>AB-rated</u> generic version of Novartis' <u>Sandostatin LAR</u>
  Depot (octreotide) intramuscular injection.
- Sandostatin LAR Depot is approved for the following indications:
  - Long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy, is not an option
  - Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
  - Long-term treatment of the profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP)-secreting tumors.
- Octreotide is also available as brand delayed-release capsules (<u>Mycapssa®</u>) and generic subcutaneous or intravenous <u>injection</u>.
  - Mycapssa is approved for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
  - Octreotide acetate injection is indicated to reduce blood levels of growth hormone and insulin growth factor-1 in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses; symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease; and treatment of the profuse watery diarrhea associated with VIP-secreting tumors.
- According to IQVIA<sup>™</sup>, Sandostatin LAR Depot had annual sales of \$826 million as of July 2024.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.